First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study - Lenz, HJ; Van Cutsem, E; Limon, ML (J Clin Oncol, 2022)
et al.